PTRXE
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Petratherm Ltd - Ent To Shares In Outback Goldfields Corp
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PTRXE
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PTRXE
N/A
PTRXE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PTRXE also invest in...
Want more shares? Try these...
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.
📊 Share price
$0.08 AUD
Petratherm Ltd. engages in the development of mineral exploration projects. The company is headquartered in Adelaide, South Australia. The company went IPO on 2004-07-27. The Company’s projects include Mabel Creek Iron-Oxide Copper-Gold, Comet Gold, Comet Rare Earth, Muckanippie, and Woomera and Arcoona Iron-Oxide Copper-Gold. The Mabel Creek Project, located approximately 50 kilometers (km) northeast of Coober Pedy in South Australia, is prospective for Iron-Oxide Copper-Gold (IOCG) and Broken Hill Type (BHT) lead-zinc-silver (Pb-Zn-Ag) mineralization. The Comet Project (EL6443, EL6633, EL6722, EL6816 & EL6818), totaling approximately 1,915 square kilometers (km2) and is located 30 km east from the recent high-grade Aurora Tank Gold discovery. The Comet Project (EL6443, EL6633, EL6722, EL6816 and EL6818) is a land holding totaling approximately 1,915 km2 in the Northern Gawler Craton of South Australia. The Muckanippie Project comprises two tenements (EL6855 and EL6815) totaling approximately 258 km2 over the central and outer portions of Muckanippie Anorthosite Complex.
📊 Share price